Abstract
Pegfilgrastim is produced by binding a 20,000-dalton polyethylene glycol molecule to granulocyte colony-stimulating factor (G-CSF), increasing the mass of the compound, and resulting in a longer-lasting form of G-CSF. This makes it more convenient to use pegfilgrastim as a single-day injection. This study was a prospective phase II single-center trial. Fifteen normal related donors received pegfilgrastim 12 mg subcutaneously to mobilize peripheral blood stem cells (PBSC) for allogeneic stem cell transplantation. Leukapheresis was planned to start 3 days after injection. All harvests were successful. Median number of leukapheresis was 2 days (range 1–3 days). There were 7/15 donors who only required single leukapheresis. The maximum concentration of white blood cells (WBC) and circulating CD34 cells occurred 3 days after pegfilgrastim injection (WBC: median 62,200/μl; CD34: median 69.76/μl). The median yield of CD34 cells was 6.78 × 106/kg recipient weight. The median CD3 cells was 1.89 × 108/kg recipient weight. The main adverse events were bone pain and headache. Median neutrophil and platelet engraftments in the recipients occurred on day 12 and day 13, respectively, after transplantation. PBSC mobilization with single-day injection of pegfilgrastim in normal donor is feasible. Further comparisons of this protocol to standard G-CSF for allogeneic stem cell mobilization should be conducted in future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ringdén O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol. 2002;20(24):4655–64.
Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98(10):2900–8.
Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T. Haematopoietic stem cell transplantation: the EBMT handbook. 5th ed. 2008. p. 112–27.
Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marr Transplant. 2008;14:301–8.
Russell N, Mesters R, Pfreundschuh M, Boogaerts M, Johnsen H, Canizo MD, et al. Pegfilgrastim (6 or 12 mg) mobilizes CD34 + cells similarly to filgrastim (5 mcg/kg/day) when administered following chemotherapy in patients with non-Hodgkin’ s lymphoma. Blood. 2005;106:11.
Kroschinsky F, Hölig K, Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apheres Sci. 2008;38:237–44.
Kroschinsky F, Hölig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34 + peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica. 2005;90:1665–71.
Hill GR, Morris ES, Fuery M, Hutchins C, Butler J, Grigg A, et al. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marr Transplant. 2006;12:603–7.
Acknowledgments
Pegfilgrastim (Neulastim) was donated by Roche Thailand.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Chanswangphuwana, C., Kupatawintu, P., Panjai, P. et al. Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. Int J Hematol 99, 318–322 (2014). https://doi.org/10.1007/s12185-014-1507-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-014-1507-0